What's new? Log in Free sign up

Bright Minds Biosciences (DRUG)

Company Profile

Company profile

Ticker

DRUG

Exchange

Website

brightmindsbio.com

CEO

Ian McDonald

Incorporated

British Columbia, Canada

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • AbbVie • Teva Pharmaceutical Industries Limited • Bausch Health Companies • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

Owl Rock Capital Corp III

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

DRUG stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign) (amended)

Bright Minds Biosciences to Present at Upcoming Conferences

Current report (foreign)

Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model

Notice of effectiveness

Shelf registration (foreign)

Condensed Interim Consolidated Financial Statements

Condensed Interim Consolidated Financial Statements

Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

Latest ownership filings

View all

Bright Minds Biosciences Inc.

Beneficial ownership report

Beneficial ownership report (amended)

Beneficial ownership report (amended)

Beneficial ownership report (amended)

RA CAPITAL MANAGEMENT, L.P.

PERCEPTIVE ADVISORS LLC

Sio Capital Management, LLC

JANUS HENDERSON GROUP PLC

Point72 Asset Management, L.P.

Financial summary

Financial statements Chart DRUG financial data

Quarter (USD)	Sep 24	Sep 23	Sep 22	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Sep 24	Sep 23	Sep 22	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

DRUG institutional ownership history Ownership history

0.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	3	6	-50.0%
Opened positions	1	0	NEW
Closed positions	4	1	+300.0%
Increased positions	0	1	EXIT
Reduced positions	1	2	-50.0%

13F shares	Current	Prev Q	Change
Total value	5.92 mm	208.19 mm	-97.2%
Total shares	5.06 k	197.54 k	-97.4%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
NA.R National Bank of Canada	4.96 k	$5.80 mm	-0.8%
Aspire Private Capital	100.00	$117.00 k	0.0%
BlackRock	1.00	$1.00 k	NEW
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
AdvisorShares Investments	0.00	-180.99 k	EXIT
Jane Street	0.00	-10.94 k	EXIT
RY Royal Bank of Canada	0.00	-510.00	EXIT
NA.R National Bank of Canada	4.96 k	-41.00	-0.8%
BlackRock	1.00	+1.00	NEW
BLK BlackRock	0.00	-1.00	EXIT
Proequities	0.00	0.00
Aspire Private Capital	100.00	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DRUG insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
4 Nov 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	21.7	184,331	4.00 mm	1,059,331
16 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	25.222	3,107	78.36 k	875,000
16 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	24.03	7,150	171.81 k	871,893
16 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	23.215	39,743	922.63 k	864,743
15 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	12.3513	4,609	56.93 k	825,000
15 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	11.7169	19,169	224.60 k	820,391
15 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	9.2624	2,700	25.01 k	801,222
15 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	8.804	2,600	22.89 k	798,522
15 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	7.3052	8,900	65.02 k	795,922
15 Oct 24	Cormorant Asset Management	Common Shares	Buy	Acquire P	Yes	No	6.4247	33,343	214.22 k	787,022

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment

https://www.marijuanamoment.net/psychedelics-show-promise-as-an-entirely-new-type-of-anti-inflammatory-treatment-research-suggests/

'New York Lawmakers Hold Hearing Psilocybin's Medical Benefits Amid Broader Debate Over Psychedelics Reform' - Marijuana Moment

https://www.marijuanamoment.net/new-york-lawmakers-hold-hearing-psilocybins-medical-benefits-amid-broader-debate-over-psychedelics-reform/

HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $85 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $85 price target.

Press releases

From Benzinga Pro

Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company's PWS program, which was announced on

Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.